Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Recruiting 3Active not recruiting 3Unknown 2Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Gemcitabine 13Radiotherapy 12Androgen Antagonists 12Specimen Handling 9Magnetic Resonance Spectroscopy 9pembrolizumab 8toripalimab 7darolutamide 7Nivolumab 7Drug Therapy 7Docetaxel 7Radiosurgery 6Cystectomy 6enzalutamide 5apalutamide 5abiraterone 5Mitomycin 5Cisplatin 5Abiraterone Acetate 5disitamab vedotin 4Pluvicto 4Cyclophosphamide 4Axitinib 4tislelizumab 3fludarabine 3enfortumab vedotin 3cemiplimab 3cabozantinib 3Sunitinib 3Standard of Care 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Congresses as Topic × Genitourinary × Clear all
NCT06129851 2023-11-13

Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer

University of Kansas Medical Center

Phase 2 Not yet recruiting
90 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡